Corcept Therapeutics Incorporated (CORT) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-30.4%

$56.33

vs $80.97 price

Levered DCF

$78.14

After debt service

Piotroski score

6 / 9

Average

Altman Z-score

30.98

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	36.63×	37.33×	31.84×	21.38×	20.41×	28.43×	14.76×	22.27×
P/B	5.58×	7.65×	6.64×	4.32×	6.09×	5.77×	3.73×	6.09×
P/S	4.75×	7.71×	6.97×	5.4×	6.26×	8.53×	4.51×	6.68×
EV / EBITDA	51.2×	31.21×	25.44×	17.58×	17.29×	22.58×	11.92×	16.41×
Gross margin	98.3%	98.4%	98.7%	98.7%	98.6%	98.4%	98.2%	97.9%
Operating margin	5.9%	20.3%	22.2%	28.0%	34.0%	36.2%	36.4%	35.6%
Net margin	13.1%	20.7%	22.0%	25.2%	30.7%	30.0%	30.7%	30.0%
Current ratio	2.92×	3.35×	4.39×	6.89×	5.6×	10.07×	7.91×	6.72×
Debt / equity	0.01×	0.01×	0×	0×	0×	0×	0.01×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	15.4%	20.6%	20.9%	20.2%	29.9%	20.3%	25.4%	27.3%
Return on invested capital	6.7%	17.1%	17.7%	19.2%	29.7%	19.6%	24.0%	26.5%
Return on assets	11.9%	16.6%	17.1%	17.4%	26.6%	18.5%	22.8%	24.2%
Free cash flow yield	3.9%	3.8%	3.8%	5.5%	7.3%	5.0%	9.8%	6.9%
Earnings yield	2.8%	2.7%	3.2%	4.7%	4.9%	3.5%	6.8%	4.5%
Enterprise value	$3.5B	$5.1B	$3.2B	$2.1B	$2.2B	$2.9B	$1.4B	$1.5B
Net debt / EBITDA	-1.67×	-0.74×	-1.07×	-0.54×	-0.6×	-0.56×	-0.24×	-2.3×
Cash conversion cycle (days)	-747	-68	-501	-356	-104	-342	-116	584